Virologic Case Studies

most efficient strategy for assessing fibrosis in patients with chronic HCV infection is to use a combination of

Until 2011, the main therapy against the infection was Pegylated-interferon (Peg-IFN) and the ribavirin (RBV) treatment (11). Interferon is a type of protein that stimulates the immune system and helps halt the virus from spreading throughout the body. Pegylated-interferon is a combination of three types of interferon, including polyethylene (PEG), which helps the treatment remain in the body for a longer time period. Ribavirin is a medication that helps stop the HCV virus from replicating. It is commonly used in combination with interferon, which is referred to as the “Peg/riba therapy.” This combination therapy is more effective than the interferon itself. However, these medications do not have a one hundred percent cure rate and it was reported

This research paper is going to review today’s silent killer, the Hepatitis C virus. This paper will talk about the description of the disease, the signs and symptoms, the etiology and risk factors, diagnostic studies, treatments and prognosis of this disease. I had lived with this disease for over ten years before diagnosed so it is important to understand the signs and symptoms so the disease can be identified and a treatment plan can be identified as the sooner it is treated the more likely it will eradicate the disease.

A few years ago, Hepatitis C was a scary term for many of us. But, today the medical problem is curable as there are various and advanced ways available. The improvement in the treatment is especially notable because experts have worked harder to obtain this success. Still, there are some significant changes are left and hopefully they will be completed soon. Presently, the HCV treatments get rid of the virus in merely slightly more than half of all sufferers. The medicines also have unnecessary side effects that make it complicated or not possible for some patients to get them. HCV medication online available, but it is not worthy to take them without the concern of the doctor.

A recombinant-based assay for the hepatitis C virus HCV has been developed, using RNA isolate from the hepatitis C virus.

Hepatitis C virus (HCV) is from the virus family Flaviviridae with an RNA envelope serving as it's genetic material. The genetic material (RNA) is HCV's pathogenic structure. The genome is positive sense single stranded RNA, which is very similar to mRNA and can be translated quickly to the host cell (Bauman 2012). Hepatitis C is an enveloped virus, and the RNA also lacks a proofreading ability after replication, which results in mutations coding for many genotypes within the host. This genetic variability makes it difficult for the host immune system to clear all the HCV infections. As one infection clears, another strain is being produced (Bauman 2012). The HCV antibody detected by ELISA(Wilkinson

domain 1) of the protein [28]. The initial rapidity with which daclatasvir reduces HCV RNA in the serum(s2 logm reduction within 6 h of administration, with a slower decline thereafter) suggests that it block virion assembly and release as well as viral RNA synthesis [29].

This review was very detailed and informative but following the first study they provided other smaller studies which were helpful in backing up their results but it didn 't provide a clear understanding to the reader. It was a cluster of studies with no explanation just information thrown into paragraphs and broken into sections. It seemed to add details to the first study but in all each study provided was essential to support their hypothesis. Overall the article was very helpful in explaining and supporting their hypothesis. It also provided a recommendation section for what future studies should focus on that will help further the knowledge of which treatment is better and why.

Although we are well aware of the mode of transmission, the hepatitis C virus itself remains a mystery. The genome of HCV is extremely mutable. Because HCV is an RNA virus and does not have adequate proofreading ability as it replicates, virions infecting humans undergo evolution with time, giving rise to the notion that HCV persists as a collection of virus quasispecies. Because it is constantly mutating, HCV is able to escape detection and elimination its human host. HCV undergoes quick mutation in a hypervariable region of the genome coding for the envelope proteins and escapes immune surveillance by the host. As a result, most HCV-infected people develop chronic infection. HCV also knocks out the host’s innate immunity.

HIV RNA (viral load) and CD4 T lymphocyte (CD4) cell count are the two surrogate markers of antiretroviral treatment (ART) responses and HIV disease progression that are used to manage and monitor HIV infection. The key goal of ART is to achieve and maintain durable viral suppression. If a patient has virologic failure, it means that they are unable to achieve or maintain suppression of viral replication to an HIV RNA level <200 copies/mL. Therefore, they should be assessed for virologic failure which include an assessment of adherence, drug-drug or drug-food interactions, drug tolerability, HIV RNA and CD4 T lymphocyte (CD4) cell count trends over time, treatment history, and prior and current drug-resistance testing results. Moreso, drug-resistance testing should be performed while the patient is taking the failing antiretroviral (ARV) regimen or within 4 weeks of treatment discontinuation.

The increasing number of citizens that are testing positive for Hepatitis C is shocking and the epidemic is just getting worse. One out of every one hundred people in the general population has Hepatitis C, but the ratio is higher in prisons. One out of every six inmates has Hepatitis C (Wegner, Rottnek, Parker and Crippin, 2014). Hepatitis C (HCV) is a blood disease that is caused by a virus and it affects the liver. Unfortunately there is no vaccine to prevent this disease and I have seen first-hand how ugly this virus is. I have worked in the medical field for the past 6 years and I have a very close friend who contracted HCV. Unfortunately, she was one of the many people that needed a liver transplant. HCV has infected four times as

The strain of genotypes is not differentiated by the severity of the disease. However, there will make a distinction in the regimen and the duration of the treatment (CDC, 2016). Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD). The criteria of who should receive the treatment include how much the virus in the body, the strain of hepatitis C, the degree of liver inflammation or damage, comorbidity, and response to previous treatment (Infectious Diseases Society of America [IDSA], 2016). The highest priority for treatment should give to a patient with advanced fibrosis and compensated cirrhosis (IDSA, 2016). Moreover, treatment priority should provide to the patient who has a high risk of transmitting the disease from and to others, such as individuals who are active injection drug users and hemodialysis patients (IDSA, 2016).

Markers of HCV infection are found in 80 to 90% of patients with hepatocellular carcinoma in Japan, 44 to 66% in Italy, and 30 to 50% in the United States (El-Serag and Rudolph,2007). It has been projected that cases of HCV-related hepatocellular carcinoma will continue to increase over the next two to three decades (El-Serag

HCV can run years or even decades and may be undiagnosed. This is the reason that until the infection progressed so far because the virus infection and low probability are causing side effects or symptoms. In many cases, we found that HCV liver injury found by regular medical

In general, a patient is infected with only one hepatitis C virus genotype. The strain of genotypes is not differentiated by the severity of the disease. However, there will make a distinction in the regimen and the duration of the treatment (CDC, 2016). Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD). The criteria of who should receive the treatment include how much the virus in the body, the strain of hepatitis C, the degree of liver inflammation or damage, comorbidity, and response to previous treatment (Infectious Diseases Society of America [IDSA], 2016). The highest priority for treatment should give to a patient with advanced fibrosis and compensated cirrhosis (IDSA, 2016). Moreover, treatment priority should provide to the patient who has a high risk of transmitting the disease from and to others, such as individuals who are active injection drug users and hemodialysis patients (IDSA, 2016).